Abstract
The present work aimed to develop and study the effect of HPMC on compression-coated floating - pulsatile delivery of Bisoprolol. Inner core tablet contains bisoprolol and a super disintegrant. Outer shell contains HPMC K4M and HPMC K100M as erodible layer along with a gas generating agent. Compression-coated tablet of bisoprolol with 120mg HPMC K4M (B2) showed a lag time of 3.40±0.1 hrs with 99.81% drug release. Whereas 110mg HPMC K100M (B5) showed a lag period 4.0±0.1 hrs with 98.91% drug release. A 32 factorial design was applied. HPMC K4M CR and K100M were independent variables whereas drug release, lag time at 4 hrs and swelling index were dependent variables. To understand the interaction of independent variables on dependent variables three dimensional surface response plots were drawn. The responses exhibited by batch F4 (55 mg HPMC K4M and 65 mg K100M) showed lag time 4.20 hrs following the sigmoidal release pattern. Optimized batch F4 gave good in-vitro in -vivo correlation.
Keywords: Bisoprolol, compression, floating tablet, HPMC, lag time, pulsatile drug delivery system.
Current Drug Therapy
Title:Study on the Effect of HPMC on Compression Coated Floating Pulsatile Delivery of Bisoprolol
Volume: 9 Issue: 2
Author(s): Swati Jagdale, Nilesh Bari, Bhanudas Kuchekar and Aniruddha Chabukswar
Affiliation:
Keywords: Bisoprolol, compression, floating tablet, HPMC, lag time, pulsatile drug delivery system.
Abstract: The present work aimed to develop and study the effect of HPMC on compression-coated floating - pulsatile delivery of Bisoprolol. Inner core tablet contains bisoprolol and a super disintegrant. Outer shell contains HPMC K4M and HPMC K100M as erodible layer along with a gas generating agent. Compression-coated tablet of bisoprolol with 120mg HPMC K4M (B2) showed a lag time of 3.40±0.1 hrs with 99.81% drug release. Whereas 110mg HPMC K100M (B5) showed a lag period 4.0±0.1 hrs with 98.91% drug release. A 32 factorial design was applied. HPMC K4M CR and K100M were independent variables whereas drug release, lag time at 4 hrs and swelling index were dependent variables. To understand the interaction of independent variables on dependent variables three dimensional surface response plots were drawn. The responses exhibited by batch F4 (55 mg HPMC K4M and 65 mg K100M) showed lag time 4.20 hrs following the sigmoidal release pattern. Optimized batch F4 gave good in-vitro in -vivo correlation.
Export Options
About this article
Cite this article as:
Jagdale Swati, Bari Nilesh, Kuchekar Bhanudas and Chabukswar Aniruddha, Study on the Effect of HPMC on Compression Coated Floating Pulsatile Delivery of Bisoprolol, Current Drug Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574885509666140115213810
DOI https://dx.doi.org/10.2174/1574885509666140115213810 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design Mice with Liver Composed of Human Hepatocytes as an Animal Model for Drug Testing
Current Drug Discovery Technologies Post-traumatic Stress Disorder in Heart Failure Patients: A Test of the Cardiac Disease-induced PTSD Hypothesis
Current Psychiatry Research and Reviews Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging The Acid Sphingomyelinase/Ceramide Pathway: Biomedical Significance and Mechanisms of Regulation
Current Molecular Medicine The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]
Current Vascular Pharmacology Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Metabolism of HDL and its Regulation
Current Medicinal Chemistry Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population
Current Neurovascular Research Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design